• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

印度出现普那霉素耐药性。

Emergence of pristinamycin resistance in India.

机构信息

Department of Pharmacology and Microbiology, Moti Lal Nehru Medical College, Allahabad, Uttar Pradesh, India.

出版信息

Indian J Pharmacol. 2009 Feb;41(1):47-8. doi: 10.4103/0253-7613.48884.

DOI:10.4103/0253-7613.48884
PMID:20177582
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2825015/
Abstract

Quinupristin and dalfopristin combination has been advocated as a drug of choice for multi-drug resistant (MDR) gram-positive cocci (GPC). We are reporting two cases of neonatal septicemia, caused by the methicillin resistant Staphylococcus aureus (MRSA), showing primary in vitro pristinamycin resistance. The Minimum inhibitory concentrations (MIC) for pristinamycin in these two cases were 30 mug and 25 mug, respectively. Universal advocacy of pristinamycin for the therapy of MDR GPC infections should be re-evaluated.

摘要

奎奴普丁-达福普汀组合已被推荐为治疗多重耐药（MDR）革兰阳性球菌（GPC）的首选药物。我们报告了两例由耐甲氧西林金黄色葡萄球菌（MRSA）引起的新生儿败血症，这些病例均表现出初始体外普雷霉素耐药性。这两例的普雷霉素最低抑菌浓度（MIC）分别为 30 微克和 25 微克。应重新评估普雷霉素作为治疗 MDR GPC 感染的普遍应用。

相似文献

1
Emergence of pristinamycin resistance in India.印度出现普那霉素耐药性。
Indian J Pharmacol. 2009 Feb;41(1):47-8. doi: 10.4103/0253-7613.48884.
2
Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.奎奴普丁/达福普汀：用于治疗严重革兰氏阳性菌感染的综述
Drugs. 1999 Dec;58(6):1061-97. doi: 10.2165/00003495-199958060-00008.
3
Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance study.针对来自拉丁美洲的革兰氏阳性球菌检测的奎奴普丁/达福普汀的抗菌药敏性：全球SMART（GSMART）监测研究结果
Braz J Infect Dis. 2001 Feb;5(1):21-31. doi: 10.1590/s1413-86702001000100004.
4
Streptogramins for the treatment of infections caused by Gram-positive pathogens.用于治疗革兰氏阳性病原体引起的感染的链阳菌素类药物。
Expert Rev Anti Infect Ther. 2021 May;19(5):587-599. doi: 10.1080/14787210.2021.1834851. Epub 2020 Oct 26.
5
In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci.利奈唑胺与奎奴普丁/达福普汀对革兰氏阳性球菌的体外活性。
Indian J Med Res. 2004 Dec;120(6):546-52.
6
In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates.奎奴普丁/达福普汀（RP59500）对医院内金黄色葡萄球菌的体外活性及杀菌作用，以及与利福平、环丙沙星对耐甲氧西林菌株的相互作用
J Antimicrob Chemother. 1998 Mar;41(3):349-55. doi: 10.1093/jac/41.3.349.
7
Emergence of Staphylococcus aureus strains resistant to pristinamycin in Sfax (Tunisia).突尼斯斯法克斯地区出现对普ristinamycin耐药的金黄色葡萄球菌菌株。
Pathol Biol (Paris). 2012 Dec;60(6):e71-4. doi: 10.1016/j.patbio.2011.10.012. Epub 2012 Jan 20.
8
Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential.奎奴普丁/达福普汀对革兰氏阳性菌的活性：临床应用及治疗潜力。
J Antimicrob Chemother. 1997 May;39 Suppl A:139-43. doi: 10.1093/jac/39.suppl_1.139.
9
A review of in-vitro antibacterial activity of quinupristin/dalfopristin against methicillin-susceptible and -resistant Staphylococcus aureus.奎奴普丁/达福普汀对甲氧西林敏感和耐药金黄色葡萄球菌的体外抗菌活性综述。
J Antimicrob Chemother. 1997 May;39 Suppl A:53-8. doi: 10.1093/jac/39.suppl_1.53.
10
Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use.奎奴普丁/达福普汀的抗菌活性。临床应用原理。
Drugs. 1996;51 Suppl 1:31-7. doi: 10.2165/00003495-199600511-00007.

引用本文的文献

1
Pristinamycin-antibiotic combinations against methicillin-resistant Staphylococcus aureus recovered from skin infections.针对从皮肤感染中分离出的耐甲氧西林金黄色葡萄球菌的普那霉素-抗生素联合用药
BMC Infect Dis. 2025 Sep 16;25(1):1107. doi: 10.1186/s12879-025-11433-0.
2
Antibiotics and bioactive natural products in treatment of methicillin resistant Staphylococcus aureus: A brief review.抗生素和生物活性天然产物在耐甲氧西林金黄色葡萄球菌治疗中的应用：简要综述
Pharmacogn Rev. 2015 Jan-Jun;9(17):29-34. doi: 10.4103/0973-7847.156329.
3
Prevalence and antimicrobial resistance pattern of methicillin resistant Staphylococcus aureus (MRSA) strains isolated from clinical specimens in Ardabil, Iran.从伊朗阿尔达比勒的临床标本中分离出的耐甲氧西林金黄色葡萄球菌（MRSA）菌株的流行情况及抗菌耐药模式
Iran J Microbiol. 2014 Jun;6(3):163-8.
4
Bacteriophage types of methicillin-resistant Staphylococcus aureus in a tertiary care hospital.一家三级护理医院中耐甲氧西林金黄色葡萄球菌的噬菌体类型
Australas Med J. 2013 Oct 31;6(10):496-503. doi: 10.4066/AMJ.2013.1742. eCollection 2013.
5
Quinpristin-Dalfopristin resistance among methicillin-resistant strains of staphylococci.耐甲氧西林葡萄球菌菌株对奎奴普丁-达福普汀的耐药性。
Indian J Pharmacol. 2010 Feb;42(1):56. doi: 10.4103/0253-7613.62403.

本文引用的文献

1
Staphylococcal resistance to streptogramins and related antibiotics.葡萄球菌对链阳菌素及相关抗生素的耐药性。
Drug Resist Updat. 1998;1(3):169-75. doi: 10.1016/s1368-7646(98)80036-8.
2
Clonal diversity among streptogramin A-resistant Staphylococcus aureus isolates collected in French hospitals.法国医院收集的对链阳菌素A耐药的金黄色葡萄球菌分离株的克隆多样性。
J Clin Microbiol. 2003 Feb;41(2):586-91. doi: 10.1128/JCM.41.2.586-591.2003.
3
In vitro activity of linezolid, quinupristin-dalfopristin, vancomycin, teicoplanin, moxifloxacin and mupirocin against methicillin-resistant Staphylococcus aureus: comparative evaluation by the E test and a broth microdilution method.利奈唑胺、奎奴普丁-达福普汀、万古霉素、替考拉宁、莫西沙星和莫匹罗星对耐甲氧西林金黄色葡萄球菌的体外活性：采用E试验和肉汤微量稀释法进行比较评价。
Diagn Microbiol Infect Dis. 2002 Aug;43(4):319-21. doi: 10.1016/s0732-8893(02)00407-8.
4
Tn5406, a new staphylococcal transposon conferring resistance to streptogramin a and related compounds including dalfopristin.Tn5406，一种新的葡萄球菌转座子，赋予对链阳性菌素A及包括达福普汀在内的相关化合物的抗性。
Antimicrob Agents Chemother. 2002 Aug;46(8):2337-43. doi: 10.1128/AAC.46.8.2337-2343.2002.
5
Resistance to quinupristin-dalfopristin due to mutation of L22 ribosomal protein in Staphylococcus aureus.金黄色葡萄球菌中L22核糖体蛋白突变导致对奎奴普丁-达福普汀耐药
Antimicrob Agents Chemother. 2002 Jul;46(7):2200-7. doi: 10.1128/AAC.46.7.2200-2207.2002.
6
Disruption of an Enterococcus faecium species-specific gene, a homologue of acquired macrolide resistance genes of staphylococci, is associated with an increase in macrolide susceptibility.粪肠球菌种特异性基因（葡萄球菌获得性大环内酯抗性基因的同源物）的破坏与大环内酯敏感性增加有关。
Antimicrob Agents Chemother. 2001 Jan;45(1):263-6. doi: 10.1128/AAC.45.1.263-266.2001.
7
Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci.莫西沙星、曲伐沙星、奎奴普丁/达福普汀及利奈唑胺对葡萄球菌的体外活性比较
J Antimicrob Chemother. 1999 Apr;43(4):569-73. doi: 10.1093/jac/43.4.569.
8
Distribution of genes encoding resistance to streptogramin A and related compounds among staphylococci resistant to these antibiotics.对链阳菌素A及相关化合物耐药的葡萄球菌中编码对这些抗生素耐药性的基因分布情况。
Antimicrob Agents Chemother. 1996 Nov;40(11):2523-8. doi: 10.1128/AAC.40.11.2523.
9
Characterisation and molecular cloning of the novel macrolide-streptogramin B resistance determinant from Staphylococcus epidermidis.表皮葡萄球菌新型大环内酯-链阳菌素B耐药决定子的鉴定与分子克隆
J Antimicrob Chemother. 1989 Dec;24(6):851-62. doi: 10.1093/jac/24.6.851.